Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Intracerebroventricular and Intravitreal Administration of NGN-101 for Treatment of Neuronal Ceroid Lipofuscinosis (NCL) Subtype 5 (CLN5) Disease

NCT05228145 is registered in ClinicalTrials.gov with Neurogene Inc. as lead sponsor.

NCT NCT05228145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05228145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Intracerebroventricular and Intravitreal Administration of NGN-101 for Treatment of Neuronal Ceroid Lipofuscinosis (NCL) Subtype 5 (CLN5) Disease
Lead sponsor
Neurogene Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 31, 2022
Completion date
November 30, 2028
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuronal ceroid lipofuscinosis cln5